Ropeg 3 yr follow-up vs HU, MPNs in patients under age of 25 at diagnosis, Targeting JAK2 mutation with IFN and Arsenic, see interview here - bit.ly/2Sa0aES
Happy Holidays,
David Wallace - PV Reporter
Dr. Jean Jacques Kiladjian ASH 2018 Research Stu... - MPN Voice
Dr. Jean Jacques Kiladjian ASH 2018 Research Studies
Written by
PVReporter
To view profiles and participate in discussions please or .
Read more about...
4 Replies
•
Thank you so much. A lot of information. Easy to understand, so much is being learnt about MPNs. Promising
Your very welcome. I think the environment is promising too!
Significant change re Ropeg. Thanks for posting
Wow more exciting research ahead
Not what you're looking for?
You may also like...
Effective INF Dose Part 2, more considerations, research, and Dr vs patient wishes
My last two doses of Bes were 70-80 mcg. In my recent Hem visit Dr was most displeased that I had...
